CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.02B, above the global median of $1.15B
- PositionCurrent ratio is 26.66×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.91%
Annual Rate
CNY 1.20Paid annual
Payout Ratio
386.8%High
Payback Period
99.0 yr
Last Ex-Dividend
May 15, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
13.61BCNY2.02B · vs all stocks (USD)
Trailing P/E
93.32xvs Biotechnology peers
Revenue (TTM)
727.69MCNY108.08M · vs all stocks (USD)
Profit Margin
21.61%vs Biotechnology peers
Beta
0.6900xvs all stocks
52-Week Change
79.14%vs all stocks
Market Capitalization
13.61BCNY2.02B · vs all stocks (USD)
Enterprise Value
13.76BCNY2.04B · vs all stocks (USD)
Trailing P/E
93.32xvs Biotechnology peers
Price to Sales (TTM)
20.28xvs Biotechnology peers
Price to Book (MRQ)
2.76xvs Biotechnology peers
Enterprise to Revenue
18.91xvs Biotechnology peers
Enterprise to EBITDA
78.82xvs Biotechnology peers
Gross Margin
75.46%vs Biotechnology peers
Profit Margin
21.61%vs Biotechnology peers
Operating Margin
17.48%vs Biotechnology peers
Return on Assets (TTM)
1.18%vs Biotechnology peers
Return on Equity (TTM)
2.83%vs Biotechnology peers
Revenue (TTM)
727.69MCNY108.08M · vs all stocks (USD)
Revenue per Share (TTM)
5.98CNYUpdated Aug 20, 2026Quarterly Revenue Growth
18.10%vs Biotechnology peers
Gross Profit (TTM)
532.39MCNY79.07M · vs all stocks (USD)
EBITDA (TTM)
167.32MCNY24.85M · vs all stocks (USD)
Net Income (TTM)
157.25MCNY23.35M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.00%vs Biotechnology peers
Operating Cash Flow (TTM)
176.81MCNY26.26M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-36.03MCNY-5.35M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.20CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.91%vs all stocks
Payout Ratio
386.76%vs Biotechnology peers
Revenue
699.56MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
186.85MCNYFY2025 · Dec 31, 2025Gross Profit
512.71MCNYFY2025 · Dec 31, 2025Operating Income
104.42MCNY15.51M · vs all stocks (USD)
Pre-tax Income
179.54MCNYFY2025 · Dec 31, 2025Income Tax Expense
31.80MCNYFY2025 · Dec 31, 2025Net Income
147.74MCNYFY2025 · Dec 31, 2025EBIT
182.63MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
259.11MCNYFY2025 · Dec 31, 2025Research & Development
86.22MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
58.35MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.51MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
3.09MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.21CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.21CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
121.63MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
121.63MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
147.74MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
117.27MCNYFY2025 · Dec 31, 2025Free Cash Flow
16.89MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
64.97MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
147.74MCNYFY2025 · Dec 31, 2025Other Non-cash Items
13.26MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-26.14MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-17.59MCNYFY2025 · Dec 31, 2025Capital Expenditures
-100.38MCNYFY2025 · Dec 31, 2025Net Acquisitions
-50.35MCNYFY2025 · Dec 31, 2025Purchase of Investments
-7.47BCNYFY2025 · Dec 31, 2025Sale of Investments
8.05BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
432.24MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-608.18MCNYFY2025 · Dec 31, 2025Other Financing Charges
-31.21MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-639.39MCNYFY2025 · Dec 31, 2025Shares Outstanding
121.64MSharesUpdated Aug 20, 2026Float Shares
43.19MSharesUpdated Aug 20, 2026% Held by Insiders
63.08%vs all stocks
% Held by Institutions
2.16%vs all stocks
Total Cash (MRQ)
3.26BCNY483.47M · vs all stocks (USD)
Total Cash per Share (MRQ)
26.76CNYUpdated Aug 20, 2026Total Debt (MRQ)
46.53MCNY6.91M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0087xvs Biotechnology peers
Current Ratio (MRQ)
26.66xvs Biotechnology peers
Book Value per Share (MRQ)
43.89CNYUpdated Aug 20, 2026Total Assets
5.54BCNY823.22M · vs all stocks (USD)
Total Current Assets
3.52BCNYFY2025 · Dec 31, 2025Total Liabilities
228.00MCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.02BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
75.28MCNYFY2025 · Dec 31, 2025Total Current Liabilities
152.73MCNYFY2025 · Dec 31, 2025Cash
317.90MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.40MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
322.30MCNYFY2025 · Dec 31, 2025Other Short-term Investments
2.90BCNYFY2025 · Dec 31, 2025Accounts Receivable
179.39MCNYFY2025 · Dec 31, 2025Inventory
79.22MCNYFY2025 · Dec 31, 2025Accounts Payable
23.72MCNYFY2025 · Dec 31, 2025Short-term Debt
22.42MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.08MCNYFY2025 · Dec 31, 2025Long-term Debt
31.10MCNYFY2025 · Dec 31, 2025Common Stock (Book)
121.64MCNYFY2025 · Dec 31, 2025Retained Earnings
775.19MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.31BCNY789.36M · vs all stocks (USD)
52-Week Low
58.05CNYUpdated Aug 20, 202652-Week High
139.49CNYUpdated Aug 20, 202652-Week Change
79.14%vs all stocks
Beta
0.6900xvs all stocks
50-Day MA
75.24CNYUpdated Aug 20, 2026200-Day MA
72.22CNYUpdated Aug 20, 2026Avg 10-Day Volume
15.02MSharesUpdated Aug 20, 2026Avg 30-Day Volume
6.92MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
1.30CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 26.66×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 26.66Industry median: 5.50Industry P95: 22.03Peers compared: 197
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.02B, above the global median of $1.15BNotable
Market cap (USD): 2,021,166,900.433Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Sk Bioscience Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Caplin Point Laboratories Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Adma Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Acro Biosystems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingFlow
Fagron NV
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Uniparts India Ltd.
1 interpretationLow-Leverage Liquidity Configuration
PT Gudang Garam Tbk
1 interpretationLow-Leverage Liquidity Configuration
MBX Biosciences, Inc.
1 interpretationLow-Leverage Liquidity Configuration